Skip to content

Arrowhead Research ARWR Gain (loss) on disposal of assets

Gain (loss) on disposal of assets at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$22.58M+1,144%
Roivant Sciences logo
Roivant SciencesROIV
$21.59M+201%
Revvity logo
RevvityRVTY
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's gain (loss) on disposal of assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's gain (loss) on disposal of assets?
Arrowhead Research (ARWR) reported gain (loss) on disposal of assets of $19M in Q1 2026.